AGENT FOR ALLEVIATING ADVERSE SIDE EFFECT PRODUCED IN INTERFERON/RIBAVIRIN COMBINATION THERAPY

摘要

PROBLEM TO BE SOLVED: To provide a prophylactic or therapeutic agent for anemia which has an adverse side effect produced in interferon/ribavirin combination therapy.;SOLUTION: An acidosis-ameliorating agent such as a preparation containing potassium citrate and sodium citrate (Uralyt-U, Uralyt Tablets (registered trade names)) is used as the prophylactic or therapeutic agent for anemia which has an adverse side effect produced in the interferon/ribavirin combination therapy. The interferon may include interferon α-2a, interferon α-2b, pegylated interferon α-2a, pegylated interferon α-2b, consensus interferon or purified interferon α.;COPYRIGHT: (C)2011,JPO&INPIT